Rossari Biotech Ltd

📈 Rossari Biotech Expands Capacity & Reports Strong Q4 FY26 Growth

• Commissioned additional 15,000 MTPA ethoxylation capacity at Dahej, bringing total capacity to 66,000 MTPA

• Q4 FY26 revenue reached ₹684.9 crore, an 18% year-over-year increase

• Full-year FY26 revenue stood at ₹2,396.4 crore, up 15% from FY25

• Q4 FY26 EBITDA was ₹77.3 crore, rising 11% year-over-year

• Q4 FY26 PAT surged to ₹46.0 crore, a 34% increase from the previous year

• Full-year FY26 PAT reached ₹149.2 crore, up 9% year-over-year

• All business segments (HPPC, TSC, AHN) delivered double-digit growth in Q4 FY26

• Established a new R&D facility in Koparkhairane, Navi Mumbai